Table 1.
Comparison of clinicopathological characteristics in the training and validation cohort.
| Characteristics | Training Cohort (n = 98) | p | Validation Cohort (n = 42) | |||
|---|---|---|---|---|---|---|
| pCR (n = 28) |
Non-pCR (n = 70) | pCR (n = 12) |
Non-pCR (n = 30) | p | ||
| Age (years) | 51.0 ± 9.1 | 51.7 ± 10.5 | 0.601 | 50.7 ± 7.2 | 47.3 ± 10.7 | 0.242 |
| Tumor size (cm) | 4.2 (3.1, 5.6) | 4.8 (3.4, 6.1) | 0.276 | 3.4 (2.5, 5.2) | 5.0 (3.1, 5.7) | 0.177 |
| Enhancement type (%) | 0.442 | 0.657 | ||||
| Mass-like | 15 (53.6) | 42 (60) | 7 (58.3) | 14 (46.7) | ||
| Non-mass-like | 6 (21.4) | 8 (11.4) | 2 (16.7) | 4 (13.3) | ||
| Mass + non-mass | 7 (25.0) | 20 (28.6) | 3 (25.0) | 12 (40.0) | ||
| Type (%) | 0.236 | 0.469 | ||||
| Multi-lesion | 8 (28.6) | 29 (41.4) | 3 (25.0) | 11 (36.7) | ||
| Single-lesion | 20 (71.4) | 41 (58.6) | 9 (75.0) | 19 (63.3) | ||
| TNM (%) | 0.276 | 0.368 | ||||
| Ⅱ A | 7 (25.0) | 9 (12.9) | 3 (25.0) | 7 (23.3) | ||
| Ⅱ B | 5 (17.9) | 18 (25.7) | 5 (41.7) | 5 (16.7) | ||
| Ⅲ A | 2 (7.1) | 11 (15.7) | 2 (16.7) | 5 (16.7) | ||
| Ⅲ B | 9 (32.1) | 26 (37.1) | 2 (16.7) | 10 (33.3) | ||
| Ⅲ C | 5 (17.9) | 6 (8.6) | 0 (0.0) | 3 (10.0) | ||
| Grades (%) | 0.104 | 0.205 | ||||
| 2 | 13 (46.4) | 45 (64.3) | 10 (83.3) | 19 (63.3) | ||
| 3 | 15 (53.6) | 25 (35.7) | 2 (16.7) | 11 (36.7) | ||
| ER status (%) | 0.001 * | 0.002 * | ||||
| Positive | 5 (17.9) | 46 (65.7) | 2 (16.7) | 21 (70.0) | ||
| Negative | 23 (82.1) | 24 (34.3) | 10 (83.3) | 9 (30.0) | ||
| PR status (%) | 0.001 * | 0.554 | ||||
| Positive | 7 (25.0) | 49 (70.0) | 7 (58.3) | 17 (56.7) | ||
| Negative | 21 (75.0) | 21 (30.0) | 5 (41.7) | 13 (43.3) | ||
| HER2 status (%) | 0.041 * | 0.008 * | ||||
| Positive | 15 (53.6) | 22 (31.4) | 8 (66.7) | 7 (23.3) | ||
| Negative | 13 (46.4) | 48 (68.6) | 4 (33.3) | 23 (76.7) | ||
| Ki-67 status (%) | 0.092 | 0.263 | ||||
| ≤20% | 2 (7.1) | 15 (21.4) | 1 (8.3) | 23 (76.7) | ||
| >20% | 26 (92.9) | 55 (78.6) | 11 (91.7) | 7 (23.3) | ||
| Molecular subtypes (%) | <0.001 * | 0.046 * | ||||
| Luminal A | 0 (0.0) | 5 (7.1) | 0 (0.0) | 2 (6.7) | ||
| Luminal B | 7 (25.0) | 48 (68.6) | 5 (41.7) | 19 (63.3) | ||
| HER2 enriched | 11 (39.3) | 5 (7.1) | 5 (41.7) | 2 (6.7) | ||
| TN | 10 (35.7) | 12 (17.2) | 2 (16.7) | 7 (23.3) | ||
Age is presented as mean ± SD. Tumor size is presented as median (interquartile range), and the others are shown as proportions (percentages). * p < 0.05. pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative.